Phase II Trial of VEGFA-Targeted BNT327 with Docetaxel in Second-line Stage IV NSCLC

BioNTech SE is conducting a Phase II, multisite (Houston recruiting now), open-label, single-arm study evaluating the safety and efficacy of BNT327—a VEGFA-directed monoclonal antibody—in combination with docetaxel, a tubulin inhibitor, for advanced NSCLC following progression on first-line chemoimmunotherapy.